Account
Insider Insights
22.02.2020
Recommendations for market access reforms

This resolution includes proposed reforms to the market access (including pricing) landscape designe...

Read more
News
09.10.2018
CSL Behring lung drug cost NHS £8m

NHS England’s cost-effectiveness watchdog, (NICE), issued a first draft document saying that it di...

Read more
Articles
28.01.2018
The arrival of gene therapies

The development of gene therapies represents a new frontier of science, with the potential to help p...

Read more
Publications
08.11.2017
NICE's modified Cancer Drugs Fund process

This study investigates the efficiency of the new CDF appraisal process for indications without prio...

Read more
Publications
24.05.2017
NICE re-evaluation of oncology drugs

This study investigates NICE's evaluation of existing CDF treatments and its potential impact on fun...

Read more
Articles
01.03.2016
Will the CDF proposals force pharma to prepare for...

From July 2016 NICE will gain decision power by saying yes, no or maybe to cancer drugs entering the...

Read more
Articles
03.03.2015
The rise of speciality products

Pharmaceutical companies are able to charge significantly higher prices as these products are addres...

Read more
Articles
28.02.2015
New frontiers for Avastin

New legislation has enabled AIFA to approve reimbursement for Avastin for off-label usage in the tre...

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.